November 17, 2022 7:47am

Ain’t easy and some times not productive yet, it’s better than doing nothing

Indications:  1 Maintaining SELL, 2 Negative Indications, 1 Positive Indication and 1 Pump/Promote

A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.

I don’t seek fame, do podcasts or give speeches, what I do is keep writing this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others won’t say or write - truth!

8:00 a.m. edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are DOWN -0.70% or (-235 points), S&P futures are DOWN -0.76% or (-30 points) and NASDAQ futures are DOWN -0.69% or (-80 points) early in the pre-open – so far,

Stock futures fell Thursday,

European markets were mixed

Asia-Pacific markets traded mostly lower



Wednesday - The Dow closed up, the S&P and Nasdaq closed down

The Dow closed DOWN -36.32 points (-0.11%), the S&P closed DOWN -32.79 points (-0.82%) while the Nasdaq closed DOWN -174.75 points (-1.54%)

Economic Data Docket: weekly jobless claims, the latest reports on October housing starts and building permits, and manufacturing surveys from the Philadelphia and Kansas City Fed bank. Ten (10) speakers from the Fed will be talking at events around the country.


Wednesday’s (11/16) … RegMed Investors’ (RMi) closing bell: “tampering and dampening share price. The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering”


Ebb and flow:

Q4 – November - 8 negative and 5 positive closes

·         October -1 neutral, 11 positive and 9 negative closes

Q3/22 –

·         September – 1 holiday, 10 positive and 11 negative closes

·         August – 1 neutral, 11 positive and 11 negative closes

·         July - 1 holiday, 10 negative and 10 positive closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Maintaining SELL:

Avrobio (AVRO) closed barely up +$0.0016 to $0.74 after Tuesday’s -$0.0218 and Monday’s -$0.03 with a negative -$0.04 or -5.24% pre-open indication. Still delisted on its 56th session but, has registered with a $250 million debt, stock, preferred, warrant etc. offering by Cowen …   


Negative Indications:

Alnylam Pharmaceuticals (ALNY) closed down -$2.30 to $211.99 with a negative -$1.99 or 0.94% pre-open indication.

CRISPR Therapeutics (CRSP) closed down -$2.25 to $58.76 after Tuesday’s +$1.23, Monday’s -$0.57, Friday’s +$5.66 and last Thursday’s +$5.76 with a negative -$0.77 or -1.31% pre-open indication


Positive Indications

Prime Medicine (PRME) closed down -$1.98 to $18.22 with a positive +$0.93 or +5.10% pre-open indication,


Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed down -$0.15 with 228 shares traded after Tuesday’s -$0.60 with 2,231 shares traded, Monday’s +$0.71 with 239 shares traded, Friday’s $0.00 with 8 shares traded to $6.19 and last Thursday’s -$0.58 with 160 shares traded <3-month average = 2,453 shares>

A DRAFT prospectus is filed … SEC Form S-1/A  … . Questions arise as to draft prospectus statement of non-reliance of past financials?  Hey, CFO Joe some of us have copies of lost “payables”?


The BOTTOM LINE: Reiterating, “I try to keep it simple … and short …

Wednesday's action offers a reason why investors should be cautious about rapidly adding exposure. Buying a bunch of new positions on one day can backfire if the market retreats, as it did Wednesday. Better to add exposure gradually, assuming the market rally and your positions are making progressing. <IBD>

Guidance on cell and gene therapy sector investing … partners, cash positions and on what percentage ownership of stock … NOT options CEOs and management teams own versus their salary and bonus.”

·         CEO salaries, spending within G&A are totally OUT-OF-WHACK; these are companies in early development stages and will be for years without products in most cases not like the tech companies, whose CEOs and management teams think sector management teams should be compared to for bi-weekly cash and “beanies”!

I also tend to be …EARLY in recommendations referencing indications; I learned very early (military), if you weren’t 5 minutes early for a meeting, you were 10 minutes late – be early in portfolio deliberations.

·         Defining the terms of my written words, “An indication can be a development of almost any kind. Specifically, it may be a confirmed fact, a possible fact, or an absence of “something”, a fragment of information or even an observation. The sole provision is that it provides insight to provide some vision into a likely course of action.”

Always’ remember and do NOT forget, today’s investors’ gold is a trader’s disposable tin.

Earnings season is all but over; the issue is “runways” or cash positions: who’s got it, who doesn’t, and when will cash run-out. With capital markets closed or tight, companies better be conserving.

Reiterating, “Kenny Storch at BTIG, states there are 226 public biotech companies trading below cash currently; with 1 out of 5 in the Nasdaq Biotech Index trading below cash.”

What’s SAFE … “No one company is immune in the sector and this market of rolling downdrafts?”

My guide to 'good news seems to be bad news' and 'bad news is good news. 'In normal times, no one really questions whether good news in the economy is actually good.

Amid the ongoing cell and gene therapy sector volatility, “our” universe’s trend remains " in a constant correction." That means that investors are safer on the sidelines as again … earnings are coming.

If you have gains, you might want to lock-in profit (if any) … before earnings season begins!

Insight is about understanding perception and also about putting into context what is relevant to expectation fulfillment


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.